This randomized trial of high risk patients with small clinial stage I cancers randomized pts to sublobar resection with or without adjuvant brachytherapy. The median follow-up for 222 pts was 4.4 years. 3 year survival was identical (71%) between the groups. There was no difference in time to local recurrence. Brachytherapy did not significantly reduce the incidence of local recurrence, even in patients with close or involved margins.
You are here:
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non-Small-Cell Lung Cancer
Submitted by: Mark Ferguson
Source: Journal of Clinical Oncology
Keywords:
Author(s): Hiran C. Fernando,
Rodney J. Landreneau,
Sumithra J. Mandrekar,
Francis C. Nichols,
Shauna L. Hillman,
Dwight E. Heron,
Bryan F. Meyers,
Thomas A. DiPetrillo,
David R. Jones,
Sandra L. Starnes,
Angelina D. Tan,
Benedict D.T. Daly and
Joe B. Putnam Jr
